DOXYCYCLINE HYCLATE

Post-LOE

doxycycline hyclate

Pfizer

ANDAORALTABLET, DELAYED RELEASE

Approved

Nov 2016

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DOXYCYCLINE HYCLATE (doxycycline hyclate) by Pfizer is 12. Approved for rocky mountain spotted fever, typhus fever, the typhus group and 19 more indications. First approved in 2016.

Drug data last refreshed 20h ago

Mechanism of Action

12.1 Mechanism of Action Doxycycline is a tetracycline-class antimicrobial drug [see Microbiology ()] . 12.3 Pharmacokinetics Following single and multiple-dose administration of doxycycline hyclate delayed-release tablets, 200 mg to adult volunteers, average peak plasma doxycycline concentration…

Worked on DOXYCYCLINE HYCLATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (2)

NCT01087476Phase 2Unknown

Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate

Started May 2010

164 enrolled

Mucositis

NCT00688064Phase 3Completed

Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris

Started Aug 2008

459 enrolled

Severe Acne Vulgaris

DOXYCYCLINE HYCLATE

Mechanism of Action

Indications (21)

Clinical Trials (2)